Principal Investigator: Angela Wang
Keywords: Trapeziectomy , Pain Relief , Opioids , Ibuprofen , Acetaminophen , Oxycodone Department: Orthopedic Surgery Operations
IRB Number: 00144754
Specialty: Orthopaedic Surgery
Sub Specialties: Hand Surgery
Recruitment Status: Not yet recruiting

Contact Information

Jayden Brennan

Brief Summary

In the US, pain management post surgery for surgical treatment of osteoarthritis at the base of the thumb, also known as trapeziectomy, typically consists of prescription opioids during the early post-op recovery phase. Given the highly addictive nature of prescription opioids, guidelines are being evaluated by hand surgeons to try to reduce the amount of opioids prescribed while still maintaining pain control after surgery. A different approach to reduce opioid use post-surgically is using non narcotic medication as a first line of treatment when managing post operative pain. The purpose of this study is to demonstrate the efficacy of using a combination of ibuprofen and acetaminophen in comparison to oxycodone for pain management in the first 30 day post-operative period. 

Inclusion Criteria

Adult >45 y.o., is undergoing trapeziectomy (aka CMC arthroplasty) for oesteoarthritis, english speaking. 

Participants who take aspirin as a blood thinning medication are still included as this is an elective surgery. Patients are able to safely take 81 mg of aspirin with ibuprofen. 

Exclusion Criteria

Pregnancy, current use of opioids in the last two weeks prior to surgery, concurrent surgeries (ex. trapeziectomy combined with carpal tunnel release), inability to complete study forms (education, cognitive ability, mental status, medical status), allergy or intolerance to Ibuprofen, Acetaminophen and/or Oxycodone, liver or kidney dysfunction, abnormal liver enzymes restricting use of acetaminophen or ibuprofen, history of chronic heart failure, gastrointestinal bleeding or coagulopathy, history of complex regional pain syndrome. 

The drugs to be concerned about are Coumadin, Warfarin and novel oral anticoagulants such as Eliquis and Xarelto as many of these are resumed soon after surgery and would potentially overlap with the ingestion of the study IP. Patients who take these medications will be excluded from the study. 

It will be up to our clinical team to review their patient's medical records for SMH of CKD (kidney dysfunction) before recommending they be enrolled in this study.